Steris PLC STE
We take great care to ensure that the data presented and summarized in this overview for STERIS plc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding STE
View all-
Vanguard Group Inc Valley Forge, PA12MShares$2.9 Billion0.05% of portfolio
-
Black Rock Inc. New York, NY9.19MShares$2.23 Billion0.05% of portfolio
-
Massachusetts Financial Services CO Boston, MA5.44MShares$1.32 Billion0.44% of portfolio
-
Wcm Investment Management, LLC Laguna Beach, CA4.5MShares$1.09 Billion2.97% of portfolio
-
State Street Corp Boston, MA4.09MShares$992 Million0.04% of portfolio
-
Morgan Stanley New York, NY3.89MShares$944 Million0.06% of portfolio
-
Generation Investment Management LLP London, X03.35MShares$814 Million4.72% of portfolio
-
Geode Capital Management, LLC Boston, MA2.43MShares$590 Million0.04% of portfolio
-
Select Equity Group, L.P. New York, NY2.22MShares$538 Million2.52% of portfolio
-
Apg Asset Management N.V. Amsterdam, P71.57MShares$381 Million1.05% of portfolio
Latest Institutional Activity in STE
Top Purchases
Top Sells
About STE
STERIS plc provides infection prevention and other procedural products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier and sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The Dental segment provides hand and powered dental instruments, infection control products, personal protective equipment, and water quality products for dental suite. The company serves its products and services to hospitals, other healthcare providers, and pharmaceutical manufacturers. The company was founded in 1985 and is based in Dublin, Ireland.
Insider Transactions at STE
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jun 13
2025
|
John Adam Zangerle Sr. VP, Gen Counsel, and Sec. |
SELL
Open market or private sale
|
Direct |
1,978
-2.79%
|
$476,698
$241.12 P/Share
|
Jun 05
2025
|
Daniel A Carestio President and CEO |
SELL
Open market or private sale
|
Direct |
17,626
-9.36%
|
$4,265,492
$242.67 P/Share
|
Jun 04
2025
|
Julia Madsen Sr. VP and GM, Life Sciences |
SELL
Payment of exercise price or tax liability
|
Direct |
194
-1.77%
|
$46,948
$242.1 P/Share
|
Jun 04
2025
|
Michael J Tokich Sr. Vice Pres., CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
341
-0.77%
|
$82,522
$242.1 P/Share
|
Jun 04
2025
|
Daniel A Carestio President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,921
-2.71%
|
$464,882
$242.1 P/Share
|
Jun 04
2025
|
Kenneth E Kohler SVP & GM, AST |
SELL
Payment of exercise price or tax liability
|
Direct |
154
-2.22%
|
$37,268
$242.1 P/Share
|
Jun 04
2025
|
Karen L Burton VP & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
92
-1.51%
|
$22,264
$242.1 P/Share
|
Jun 04
2025
|
Renato Tamaro V.P. & Corporate Treasurer |
SELL
Payment of exercise price or tax liability
|
Direct |
66
-0.91%
|
$15,972
$242.1 P/Share
|
Jun 04
2025
|
John Adam Zangerle Sr. VP, Gen Counsel, and Sec. |
SELL
Payment of exercise price or tax liability
|
Direct |
425
-1.18%
|
$102,850
$242.1 P/Share
|
Jun 03
2025
|
Kenneth E Kohler SVP & GM, AST |
BUY
Grant, award, or other acquisition
|
Direct |
1,890
+21.43%
|
-
|
Jun 03
2025
|
Cary L Majors SVP and President, Healthcare |
BUY
Grant, award, or other acquisition
|
Direct |
2,922
+17.55%
|
-
|
Jun 03
2025
|
Renato Tamaro V.P. & Corporate Treasurer |
BUY
Grant, award, or other acquisition
|
Direct |
651
+8.2%
|
-
|
Jun 03
2025
|
Mary Clare Fraser SVP & Chief HRO |
BUY
Grant, award, or other acquisition
|
Direct |
2,505
+16.06%
|
-
|
Jun 03
2025
|
Michael J Tokich Sr. Vice Pres., CFO |
BUY
Grant, award, or other acquisition
|
Direct |
2,223
+4.79%
|
-
|
Jun 03
2025
|
Julia Madsen Sr. VP and GM, Life Sciences |
BUY
Grant, award, or other acquisition
|
Direct |
1,998
+15.42%
|
-
|
Jun 03
2025
|
John Adam Zangerle Sr. VP, Gen Counsel, and Sec. |
BUY
Grant, award, or other acquisition
|
Direct |
3,756
+9.41%
|
-
|
Jun 03
2025
|
Karen L Burton VP & CAO |
BUY
Grant, award, or other acquisition
|
Direct |
1,953
+24.29%
|
-
|
Jun 03
2025
|
Daniel A Carestio President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
17,811
+20.07%
|
-
|
Jun 02
2025
|
Cary L Majors SVP and President, Healthcare |
SELL
Payment of exercise price or tax liability
|
Direct |
564
-4.96%
|
$136,488
$242.08 P/Share
|
Jun 02
2025
|
Renato Tamaro V.P. & Corporate Treasurer |
SELL
Payment of exercise price or tax liability
|
Direct |
165
-0.82%
|
$39,930
$242.08 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 60K shares |
---|---|
Exercise of conversion of derivative security | 36.2K shares |
Open market or private sale | 81.3K shares |
---|---|
Payment of exercise price or tax liability | 10.8K shares |